<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1710">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387786</url>
  </required_header>
  <id_info>
    <org_study_id>216</org_study_id>
    <nct_id>NCT04387786</nct_id>
  </id_info>
  <brief_title>Dornase Alfa Administered to Patients With COVID-19 (DACOVID)</brief_title>
  <acronym>DACOVID</acronym>
  <official_title>Nebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients: A Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Feinstein Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cold Spring Harbor Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of
      24-53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase
      alfa is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is
      FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs)
      contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of
      patients with severe COVID-19, and targeting NETs reduces mortality in animal models of acute
      respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with
      severe COVID-19-acting as a mucolytic and targeting NETs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Demographic, clinical data, and outcomes were collected from the electronic medical records
      of five mechanically ventilated patients with COVID-19-including three requiring veno-venous
      extracorporeal membrane oxygenation (VV-ECMO)-treated with nebulized in-line endotracheal
      dornase alfa co-administered with albuterol (used to increase delivery to the alveoli),
      between March 31 and April 24, 2020. Data on tolerability and responses, including
      longitudinal values capturing respiratory function and inflammatory status, were analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">April 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants discharged from the intensive care unit (ICU)</measure>
    <time_frame>2 months</time_frame>
    <description>discharge from ICU will be determined from the enterprise health record reporting database</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who survived COVID-19</measure>
    <time_frame>2-4 months</time_frame>
    <description>survival will be determined from the enterprise health record reporting database</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in FiO2</measure>
    <time_frame>2 months</time_frame>
    <description>fraction of inspired oxygen requirements will be measured</description>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>COVID-19</condition>
  <condition>Mechanical Ventilation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dornase Alfa</intervention_name>
    <description>nebulized in-line endotracheal dornase alfa co-administered with albuterol</description>
    <other_name>albuterol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        mechanically ventilated patients with COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mechanically ventilated patients with COVID-19

        Exclusion Criteria:

          -  healthy, non-ventilated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betsy J Barnes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Feinstein Institute for Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Feinstein Insitute for Medical Research at Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Da√üler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020 Jun 1;217(6). pii: e20200652. doi: 10.1084/jem.20200652.</citation>
    <PMID>32302401</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Feinstein Institute for Medical Research</investigator_affiliation>
    <investigator_full_name>Betsy J Barnes</investigator_full_name>
    <investigator_title>Investigator/Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study will be published and data will be made available</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3-6 months</ipd_time_frame>
    <ipd_access_criteria>de-identified data</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

